Chao‐Hung Hung

4.4k total citations
145 papers, 2.3k citations indexed

About

Chao‐Hung Hung is a scholar working on Hepatology, Epidemiology and Oncology. According to data from OpenAlex, Chao‐Hung Hung has authored 145 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 136 papers in Hepatology, 115 papers in Epidemiology and 16 papers in Oncology. Recurrent topics in Chao‐Hung Hung's work include Liver Disease Diagnosis and Treatment (100 papers), Hepatitis C virus research (90 papers) and Hepatitis B Virus Studies (74 papers). Chao‐Hung Hung is often cited by papers focused on Liver Disease Diagnosis and Treatment (100 papers), Hepatitis C virus research (90 papers) and Hepatitis B Virus Studies (74 papers). Chao‐Hung Hung collaborates with scholars based in Taiwan, United States and Australia. Chao‐Hung Hung's co-authors include Sheng‐Nan Lu, Jing‐Houng Wang, Chien‐Hung Chen, Tsung‐Hui Hu, Chuan–Mo Lee, Chao‐Long Chen, Kwong‐Ming Kee, Yi‐Hao Yen, Yuan‐Hung Kuo and Ming‐Chao Tsai and has published in prestigious journals such as PLoS ONE, Scientific Reports and Journal of Clinical Microbiology.

In The Last Decade

Chao‐Hung Hung

139 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Chao‐Hung Hung Taiwan	25	1.9k	1.6k	280	267	242	145	2.3k
Do Young Kim South Korea	31	2.4k 1.3×	2.4k 1.5×	238 0.8×	382 1.4×	190 0.8×	111	3.0k
Kwong‐Ming Kee Taiwan	25	1.3k 0.7×	1.1k 0.7×	188 0.7×	251 0.9×	188 0.8×	87	1.6k
Ming‐Lun Yeh Taiwan	26	1.7k 0.9×	1.8k 1.1×	88 0.3×	296 1.1×	147 0.6×	193	2.4k
Chhagan Bihari India	27	1.0k 0.5×	1.1k 0.7×	183 0.7×	501 1.9×	103 0.4×	132	1.9k
Catherine Frenette United States	25	1.2k 0.6×	917 0.6×	280 1.0×	389 1.5×	185 0.8×	87	1.8k
Motohiko Tanaka Japan	15	1.4k 0.7×	1.2k 0.7×	194 0.7×	136 0.5×	96 0.4×	49	1.8k
Katharina Staufer Austria	24	966 0.5×	1.0k 0.6×	253 0.9×	329 1.2×	170 0.7×	56	1.9k
Gian Lodovico Rapaccini Italy	24	910 0.5×	1.1k 0.6×	147 0.5×	436 1.6×	98 0.4×	51	1.9k
Sae Hwan Lee South Korea	24	1.2k 0.6×	962 0.6×	173 0.6×	602 2.3×	173 0.7×	106	2.1k
P. Carucci Italy	23	1.5k 0.8×	1.9k 1.2×	362 1.3×	623 2.3×	121 0.5×	71	2.8k

Countries citing papers authored by Chao‐Hung Hung

Since Specialization

Citations

This map shows the geographic impact of Chao‐Hung Hung's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chao‐Hung Hung with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chao‐Hung Hung more than expected).

Fields of papers citing papers by Chao‐Hung Hung

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chao‐Hung Hung. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chao‐Hung Hung. The network helps show where Chao‐Hung Hung may publish in the future.

Co-authorship network of co-authors of Chao‐Hung Hung

This figure shows the co-authorship network connecting the top 25 collaborators of Chao‐Hung Hung. A scholar is included among the top collaborators of Chao‐Hung Hung based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chao‐Hung Hung. Chao‐Hung Hung is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yong, Chee‐Chien, Kwong‐Ming Kee, Sheng‐Nan Lu, et al.. (2025). Overall survival is comparable between percutaneous radiofrequency ablation and liver resection as first-line therapies for solitary 3–5 cm hepatocellular carcinoma. Langenbeck s Archives of Surgery. 410(1). 66–66. 1 indexed citations

Wu, Ming‐Shun, Wei‐Yu Kao, Shih–Jer Hsu, et al.. (2025). Consensus Guideline of Ablation for Metastatic Liver Tumors by Taiwan Academy of Tumor Ablation. Liver Cancer. 15(1). 149–164.

Hsieh, Yung‐Yu, Wei‐Ming Chen, Chien‐Heng Shen, et al.. (2024). Weight Gain and Increased Body Mass Index in Patients with Hepatitis C after Eradication Using Direct-Acting Antiviral Therapy in Taiwan. Diagnostics. 14(2). 213–213. 1 indexed citations

Hsiao, Ya‐Wen, Jing‐Houng Wang, Yen‐Hao Chen, et al.. (2023). Well‐controlled viremia reduces the progression of hepatocellular carcinoma in chronic viral hepatitis patients treated with lenvatinib. The Kaohsiung Journal of Medical Sciences. 39(12). 1233–1242. 1 indexed citations

Chen, Chun‐Hsien, Chien‐Heng Shen, Kuo‐Liang Wei, et al.. (2023). Factors Associated with Large Renal Function Decline in Patients with Chronic Hepatitis C Successfully Treated with Direct-Acting Antiviral Therapy. Diagnostics. 13(3). 473–473. 1 indexed citations

Hsieh, Yung‐Yu, Wei‐Ming Chen, Te‐Sheng Chang, et al.. (2023). Direct-Acting Antivirals Reduce the De Novo Development of Esophageal Varices in Patients with Hepatitis C Virus Related Liver Cirrhosis. Viruses. 15(1). 252–252. 3 indexed citations

Yao, Chih‐Chien, Jing‐Houng Wang, Chien‐Hung Chen, et al.. (2023). Short Half-Life of Des-γ-Carboxy Prothrombin Is a Superior Factor for Early Prediction of Outcomes of Hepatocellular Carcinoma Treated with Radiofrequency Ablation. Diagnostics. 13(4). 696–696. 2 indexed citations

Lu, Chung‐Kuang, Yung‐Yu Hsieh, Shui‐Yi Tung, et al.. (2022). Comparison of 8- versus 12-weeks of glecaprevir/pibrentasvir for Taiwanese patients with hepatitis C and compensated cirrhosis in a real-world setting. PLoS ONE. 17(8). e0272567–e0272567. 2 indexed citations

Jeng, Wen‐Juei, Tsung‐Hui Hu, Jing‐Houng Wang, et al.. (2022). Combined baseline HBcrAg and end-of-treatment HBsAg predict HBV relapse after entecavir or tenofovir cessation. Journal of Antimicrobial Chemotherapy. 78(2). 436–439. 2 indexed citations

10.

Chen, Wei‐Ming, Kuo‐Liang Wei, Shui‐Yi Tung, et al.. (2020). High viral load predicts virologic failure in chronic genotype 2 hepatitis C virus-infected patients receiving glecaprevir/pibrentasvir therapy. Journal of the Formosan Medical Association. 119(11). 1593–1600. 4 indexed citations

11.

Chang, Te‐Sheng, Chao‐Hung Hung, Wei‐Ming Chen, et al.. (2020). Usefulness of quantitative hepatitis B surface antigen testing in hepatitis B community-based screening. Journal of the Formosan Medical Association. 120(2). 847–853. 3 indexed citations

12.

Hu, Tsung‐Hui, Sherry Yueh‐Hsia Chiu, Po‐Lin Tseng, et al.. (2020). Five‐year comparative risk of hepatocellular carcinoma development under entecavir or tenofovir treatment‐naïve patients with chronic hepatitis B‐related compensated cirrhosis in Taiwan. Alimentary Pharmacology & Therapeutics. 52(11-12). 1695–1706. 14 indexed citations

13.

Tsai, Ming‐Chao, Chun‐Yen Lin, Chien‐Hung Chen, et al.. (2020). Serial changes of renal function after directly acting antivirals treatment for chronic hepatitis C: A 1-year follow-up study after treatment. PLoS ONE. 15(4). e0231102–e0231102. 11 indexed citations

14.

Chen, Wei‐Ming, et al.. (2019). Esophageal perforation caused by a central venous catheter: A case report and literature review. Advances in digestive medicine. 7(2). 93–96.

15.

Huang, Pao‐Yuan, Chih‐Chi Wang, Chih‐Che Lin, et al.. (2019). Predictive Effects of Inflammatory Scores in Patients with BCLC 0-A Hepatocellular Carcinoma after Hepatectomy. Journal of Clinical Medicine. 8(10). 1676–1676. 24 indexed citations

16.

Yen, Yi‐Hao, Ming‐Tsung Lin, Fang‐Ying Kuo, et al.. (2017). The association between steatosis and diabetes with hepatocellular carcinoma in non‐genotype 3 chronic hepatitis C patients. Liver International. 38(6). 1064–1073. 14 indexed citations

17.

Hu, Tsung‐Hui, Kuo‐Chin Chang, Po‐Lin Tseng, et al.. (2017). Dynamic noninvasive markers predict hepatocellular carcinoma in chronic hepatitis C patients without sustained virological response after interferon-based therapy. Medicine. 96(46). e8696–e8696. 9 indexed citations

18.

Wang, Jing‐Houng, Seng‐Kee Chuah, Sheng‐Nan Lu, et al.. (2014). Baseline and serial liver stiffness measurement in prediction of portal hypertension progression for patients with compensated cirrhosis. Liver International. 34(9). 1340–1348. 36 indexed citations

19.

Lu, Shin-Yu, et al.. (2009). Increased oral lichen planus in a chronic hepatitis patient associated with elevated transaminase levels before and after interferon/ribavirin therapy. Journal of Dental Sciences. 4(4). 191–197. 5 indexed citations

20.

Tai, Wei‐Chen, Tsung‐Hui Hu, Jing‐Houng Wang, et al.. (2009). Clinical Implications of Alpha-fetoprotein in Chronic Hepatitis C. Journal of the Formosan Medical Association. 108(3). 210–218. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact